The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Psychiatric Long-acting Injection Market Research Report 2025

Global Psychiatric Long-acting Injection Market Research Report 2025

Publishing Date : Mar, 2025

License Type :

Report Code : 1983748

No of Pages : 89

Ask Your Query

Report Description
Table of Content

Synopsis
The global Psychiatric Long-acting Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Psychiatric Long-acting Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Psychiatric Long-acting Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Psychiatric Long-acting Injection include Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., Lundbeck, Eli Lilly, Alkermes, Par Pharmaceutical, AbbVie, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Psychiatric Long-acting Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychiatric Long-acting Injection.
The Psychiatric Long-acting Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Psychiatric Long-acting Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Psychiatric Long-acting Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Oakwood Labs
Teva
MedinCell
Janssen
Otsuka America Pharmaceutical, Inc.
Lundbeck
Eli Lilly
Alkermes
Par Pharmaceutical
AbbVie
Luye Pharmaceutical
Segment by Type
Aripiprazole Long-acting Injection
Haloperidol Long-acting Injection
Paliperidone Long-acting Injection
Risperidone Long-acting Injection
Olanzapine Long-acting Injection
Others
Segment by Application
Schizophrenia
Bipolar Disorder
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Psychiatric Long-acting Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Psychiatric Long-acting Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Psychiatric Long-acting Injection Market Overview
1.1 Product Definition
1.2 Psychiatric Long-acting Injection by Type
1.2.1 Global Psychiatric Long-acting Injection Market Value Comparison by Type (2024-2030)
1.2.2 Aripiprazole Long-acting Injection
1.2.3 Haloperidol Long-acting Injection
1.2.4 Paliperidone Long-acting Injection
1.2.5 Risperidone Long-acting Injection
1.2.6 Olanzapine Long-acting Injection
1.2.7 Others
1.3 Psychiatric Long-acting Injection by Application
1.3.1 Global Psychiatric Long-acting Injection Market Value by Application (2024-2030)
1.3.2 Schizophrenia
1.3.3 Bipolar Disorder
1.3.4 Others
1.4 Global Psychiatric Long-acting Injection Market Size Estimates and Forecasts
1.4.1 Global Psychiatric Long-acting Injection Revenue 2019-2030
1.4.2 Global Psychiatric Long-acting Injection Sales 2019-2030
1.4.3 Global Psychiatric Long-acting Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Psychiatric Long-acting Injection Market Competition by Manufacturers
2.1 Global Psychiatric Long-acting Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global Psychiatric Long-acting Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Psychiatric Long-acting Injection Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Psychiatric Long-acting Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Psychiatric Long-acting Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Psychiatric Long-acting Injection, Product Type & Application
2.7 Global Key Manufacturers of Psychiatric Long-acting Injection, Date of Enter into This Industry
2.8 Global Psychiatric Long-acting Injection Market Competitive Situation and Trends
2.8.1 Global Psychiatric Long-acting Injection Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Psychiatric Long-acting Injection Players Market Share by Revenue
2.8.3 Global Psychiatric Long-acting Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Psychiatric Long-acting Injection Market Scenario by Region
3.1 Global Psychiatric Long-acting Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Psychiatric Long-acting Injection Sales by Region: 2019-2030
3.2.1 Global Psychiatric Long-acting Injection Sales by Region: 2019-2024
3.2.2 Global Psychiatric Long-acting Injection Sales by Region: 2025-2030
3.3 Global Psychiatric Long-acting Injection Revenue by Region: 2019-2030
3.3.1 Global Psychiatric Long-acting Injection Revenue by Region: 2019-2024
3.3.2 Global Psychiatric Long-acting Injection Revenue by Region: 2025-2030
3.4 North America Psychiatric Long-acting Injection Market Facts & Figures by Country
3.4.1 North America Psychiatric Long-acting Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Psychiatric Long-acting Injection Sales by Country (2019-2030)
3.4.3 North America Psychiatric Long-acting Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Psychiatric Long-acting Injection Market Facts & Figures by Country
3.5.1 Europe Psychiatric Long-acting Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Psychiatric Long-acting Injection Sales by Country (2019-2030)
3.5.3 Europe Psychiatric Long-acting Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Psychiatric Long-acting Injection Market Facts & Figures by Region
3.6.1 Asia Pacific Psychiatric Long-acting Injection Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Psychiatric Long-acting Injection Sales by Region (2019-2030)
3.6.3 Asia Pacific Psychiatric Long-acting Injection Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Psychiatric Long-acting Injection Market Facts & Figures by Country
3.7.1 Latin America Psychiatric Long-acting Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Psychiatric Long-acting Injection Sales by Country (2019-2030)
3.7.3 Latin America Psychiatric Long-acting Injection Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Psychiatric Long-acting Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Psychiatric Long-acting Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Psychiatric Long-acting Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Psychiatric Long-acting Injection Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Psychiatric Long-acting Injection Sales by Type (2019-2030)
4.1.1 Global Psychiatric Long-acting Injection Sales by Type (2019-2024)
4.1.2 Global Psychiatric Long-acting Injection Sales by Type (2025-2030)
4.1.3 Global Psychiatric Long-acting Injection Sales Market Share by Type (2019-2030)
4.2 Global Psychiatric Long-acting Injection Revenue by Type (2019-2030)
4.2.1 Global Psychiatric Long-acting Injection Revenue by Type (2019-2024)
4.2.2 Global Psychiatric Long-acting Injection Revenue by Type (2025-2030)
4.2.3 Global Psychiatric Long-acting Injection Revenue Market Share by Type (2019-2030)
4.3 Global Psychiatric Long-acting Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Psychiatric Long-acting Injection Sales by Application (2019-2030)
5.1.1 Global Psychiatric Long-acting Injection Sales by Application (2019-2024)
5.1.2 Global Psychiatric Long-acting Injection Sales by Application (2025-2030)
5.1.3 Global Psychiatric Long-acting Injection Sales Market Share by Application (2019-2030)
5.2 Global Psychiatric Long-acting Injection Revenue by Application (2019-2030)
5.2.1 Global Psychiatric Long-acting Injection Revenue by Application (2019-2024)
5.2.2 Global Psychiatric Long-acting Injection Revenue by Application (2025-2030)
5.2.3 Global Psychiatric Long-acting Injection Revenue Market Share by Application (2019-2030)
5.3 Global Psychiatric Long-acting Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Oakwood Labs
6.1.1 Oakwood Labs Company Information
6.1.2 Oakwood Labs Description and Business Overview
6.1.3 Oakwood Labs Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Oakwood Labs Psychiatric Long-acting Injection Product Portfolio
6.1.5 Oakwood Labs Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Teva Psychiatric Long-acting Injection Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 MedinCell
6.3.1 MedinCell Company Information
6.3.2 MedinCell Description and Business Overview
6.3.3 MedinCell Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 MedinCell Psychiatric Long-acting Injection Product Portfolio
6.3.5 MedinCell Recent Developments/Updates
6.4 Janssen
6.4.1 Janssen Company Information
6.4.2 Janssen Description and Business Overview
6.4.3 Janssen Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Janssen Psychiatric Long-acting Injection Product Portfolio
6.4.5 Janssen Recent Developments/Updates
6.5 Otsuka America Pharmaceutical, Inc.
6.5.1 Otsuka America Pharmaceutical, Inc. Company Information
6.5.2 Otsuka America Pharmaceutical, Inc. Description and Business Overview
6.5.3 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product Portfolio
6.5.5 Otsuka America Pharmaceutical, Inc. Recent Developments/Updates
6.6 Lundbeck
6.6.1 Lundbeck Company Information
6.6.2 Lundbeck Description and Business Overview
6.6.3 Lundbeck Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Lundbeck Psychiatric Long-acting Injection Product Portfolio
6.6.5 Lundbeck Recent Developments/Updates
6.7 Eli Lilly
6.7.1 Eli Lilly Company Information
6.7.2 Eli Lilly Description and Business Overview
6.7.3 Eli Lilly Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Eli Lilly Psychiatric Long-acting Injection Product Portfolio
6.7.5 Eli Lilly Recent Developments/Updates
6.8 Alkermes
6.8.1 Alkermes Company Information
6.8.2 Alkermes Description and Business Overview
6.8.3 Alkermes Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Alkermes Psychiatric Long-acting Injection Product Portfolio
6.8.5 Alkermes Recent Developments/Updates
6.9 Par Pharmaceutical
6.9.1 Par Pharmaceutical Company Information
6.9.2 Par Pharmaceutical Description and Business Overview
6.9.3 Par Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Par Pharmaceutical Psychiatric Long-acting Injection Product Portfolio
6.9.5 Par Pharmaceutical Recent Developments/Updates
6.10 AbbVie
6.10.1 AbbVie Company Information
6.10.2 AbbVie Description and Business Overview
6.10.3 AbbVie Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.10.4 AbbVie Psychiatric Long-acting Injection Product Portfolio
6.10.5 AbbVie Recent Developments/Updates
6.11 Luye Pharmaceutical
6.11.1 Luye Pharmaceutical Company Information
6.11.2 Luye Pharmaceutical Description and Business Overview
6.11.3 Luye Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Luye Pharmaceutical Psychiatric Long-acting Injection Product Portfolio
6.11.5 Luye Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Psychiatric Long-acting Injection Industry Chain Analysis
7.2 Psychiatric Long-acting Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Psychiatric Long-acting Injection Production Mode & Process
7.4 Psychiatric Long-acting Injection Sales and Marketing
7.4.1 Psychiatric Long-acting Injection Sales Channels
7.4.2 Psychiatric Long-acting Injection Distributors
7.5 Psychiatric Long-acting Injection Customers
8 Psychiatric Long-acting Injection Market Dynamics
8.1 Psychiatric Long-acting Injection Industry Trends
8.2 Psychiatric Long-acting Injection Market Drivers
8.3 Psychiatric Long-acting Injection Market Challenges
8.4 Psychiatric Long-acting Injection Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Psychiatric Long-acting Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Psychiatric Long-acting Injection Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Psychiatric Long-acting Injection Market Competitive Situation by Manufacturers in 2023
Table 4. Global Psychiatric Long-acting Injection Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Psychiatric Long-acting Injection Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Psychiatric Long-acting Injection Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Psychiatric Long-acting Injection Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Psychiatric Long-acting Injection, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Psychiatric Long-acting Injection, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Psychiatric Long-acting Injection, Product Type & Application
Table 12. Global Key Manufacturers of Psychiatric Long-acting Injection, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Psychiatric Long-acting Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychiatric Long-acting Injection as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Psychiatric Long-acting Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Psychiatric Long-acting Injection Sales by Region (2019-2024) & (K Units)
Table 18. Global Psychiatric Long-acting Injection Sales Market Share by Region (2019-2024)
Table 19. Global Psychiatric Long-acting Injection Sales by Region (2025-2030) & (K Units)
Table 20. Global Psychiatric Long-acting Injection Sales Market Share by Region (2025-2030)
Table 21. Global Psychiatric Long-acting Injection Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Psychiatric Long-acting Injection Revenue Market Share by Region (2019-2024)
Table 23. Global Psychiatric Long-acting Injection Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Psychiatric Long-acting Injection Revenue Market Share by Region (2025-2030)
Table 25. North America Psychiatric Long-acting Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 27. North America Psychiatric Long-acting Injection Sales by Country (2025-2030) & (K Units)
Table 28. North America Psychiatric Long-acting Injection Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Psychiatric Long-acting Injection Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Psychiatric Long-acting Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 32. Europe Psychiatric Long-acting Injection Sales by Country (2025-2030) & (K Units)
Table 33. Europe Psychiatric Long-acting Injection Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Psychiatric Long-acting Injection Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Psychiatric Long-acting Injection Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Psychiatric Long-acting Injection Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Psychiatric Long-acting Injection Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Psychiatric Long-acting Injection Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Psychiatric Long-acting Injection Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Psychiatric Long-acting Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Psychiatric Long-acting Injection Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Psychiatric Long-acting Injection Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Psychiatric Long-acting Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 47. Middle East and Africa Psychiatric Long-acting Injection Sales by Country (2025-2030) & (K Units)
Table 48. Middle East and Africa Psychiatric Long-acting Injection Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Psychiatric Long-acting Injection Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Psychiatric Long-acting Injection Sales (K Units) by Type (2019-2024)
Table 51. Global Psychiatric Long-acting Injection Sales (K Units) by Type (2025-2030)
Table 52. Global Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Table 53. Global Psychiatric Long-acting Injection Sales Market Share by Type (2025-2030)
Table 54. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2019-2024)
Table 57. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2025-2030)
Table 58. Global Psychiatric Long-acting Injection Price (US$/Unit) by Type (2019-2024)
Table 59. Global Psychiatric Long-acting Injection Price (US$/Unit) by Type (2025-2030)
Table 60. Global Psychiatric Long-acting Injection Sales (K Units) by Application (2019-2024)
Table 61. Global Psychiatric Long-acting Injection Sales (K Units) by Application (2025-2030)
Table 62. Global Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Table 63. Global Psychiatric Long-acting Injection Sales Market Share by Application (2025-2030)
Table 64. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Psychiatric Long-acting Injection Revenue Market Share by Application (2019-2024)
Table 67. Global Psychiatric Long-acting Injection Revenue Market Share by Application (2025-2030)
Table 68. Global Psychiatric Long-acting Injection Price (US$/Unit) by Application (2019-2024)
Table 69. Global Psychiatric Long-acting Injection Price (US$/Unit) by Application (2025-2030)
Table 70. Oakwood Labs Company Information
Table 71. Oakwood Labs Description and Business Overview
Table 72. Oakwood Labs Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Oakwood Labs Psychiatric Long-acting Injection Product
Table 74. Oakwood Labs Recent Developments/Updates
Table 75. Teva Company Information
Table 76. Teva Description and Business Overview
Table 77. Teva Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Teva Psychiatric Long-acting Injection Product
Table 79. Teva Recent Developments/Updates
Table 80. MedinCell Company Information
Table 81. MedinCell Description and Business Overview
Table 82. MedinCell Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. MedinCell Psychiatric Long-acting Injection Product
Table 84. MedinCell Recent Developments/Updates
Table 85. Janssen Company Information
Table 86. Janssen Description and Business Overview
Table 87. Janssen Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Janssen Psychiatric Long-acting Injection Product
Table 89. Janssen Recent Developments/Updates
Table 90. Otsuka America Pharmaceutical, Inc. Company Information
Table 91. Otsuka America Pharmaceutical, Inc. Description and Business Overview
Table 92. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product
Table 94. Otsuka America Pharmaceutical, Inc. Recent Developments/Updates
Table 95. Lundbeck Company Information
Table 96. Lundbeck Description and Business Overview
Table 97. Lundbeck Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Lundbeck Psychiatric Long-acting Injection Product
Table 99. Lundbeck Recent Developments/Updates
Table 100. Eli Lilly Company Information
Table 101. Eli Lilly Description and Business Overview
Table 102. Eli Lilly Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Eli Lilly Psychiatric Long-acting Injection Product
Table 104. Eli Lilly Recent Developments/Updates
Table 105. Alkermes Company Information
Table 106. Alkermes Description and Business Overview
Table 107. Alkermes Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Alkermes Psychiatric Long-acting Injection Product
Table 109. Alkermes Recent Developments/Updates
Table 110. Par Pharmaceutical Company Information
Table 111. Par Pharmaceutical Description and Business Overview
Table 112. Par Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Par Pharmaceutical Psychiatric Long-acting Injection Product
Table 114. Par Pharmaceutical Recent Developments/Updates
Table 115. AbbVie Company Information
Table 116. AbbVie Description and Business Overview
Table 117. AbbVie Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. AbbVie Psychiatric Long-acting Injection Product
Table 119. AbbVie Recent Developments/Updates
Table 120. Luye Pharmaceutical Company Information
Table 121. Luye Pharmaceutical Description and Business Overview
Table 122. Luye Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Luye Pharmaceutical Psychiatric Long-acting Injection Product
Table 124. Luye Pharmaceutical Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Psychiatric Long-acting Injection Distributors List
Table 128. Psychiatric Long-acting Injection Customers List
Table 129. Psychiatric Long-acting Injection Market Trends
Table 130. Psychiatric Long-acting Injection Market Drivers
Table 131. Psychiatric Long-acting Injection Market Challenges
Table 132. Psychiatric Long-acting Injection Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report

List of Figures
Figure 1. Product Picture of Psychiatric Long-acting Injection
Figure 2. Global Psychiatric Long-acting Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Psychiatric Long-acting Injection Market Share by Type: 2023 & 2030
Figure 4. Aripiprazole Long-acting Injection Product Picture
Figure 5. Haloperidol Long-acting Injection Product Picture
Figure 6. Paliperidone Long-acting Injection Product Picture
Figure 7. Risperidone Long-acting Injection Product Picture
Figure 8. Olanzapine Long-acting Injection Product Picture
Figure 9. Others Product Picture
Figure 10. Global Psychiatric Long-acting Injection Market Value by Application (2024-2030) & (US$ Million)
Figure 11. Global Psychiatric Long-acting Injection Market Share by Application: 2023 & 2030
Figure 12. Schizophrenia
Figure 13. Bipolar Disorder
Figure 14. Others
Figure 15. Global Psychiatric Long-acting Injection Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Psychiatric Long-acting Injection Market Size (2019-2030) & (US$ Million)
Figure 17. Global Psychiatric Long-acting Injection Sales (2019-2030) & (K Units)
Figure 18. Global Psychiatric Long-acting Injection Average Price (US$/Unit) & (2019-2030)
Figure 19. Psychiatric Long-acting Injection Report Years Considered
Figure 20. Psychiatric Long-acting Injection Sales Share by Manufacturers in 2023
Figure 21. Global Psychiatric Long-acting Injection Revenue Share by Manufacturers in 2023
Figure 22. Global 5 and 10 Largest Psychiatric Long-acting Injection Players: Market Share by Revenue in Psychiatric Long-acting Injection in 2023
Figure 23. Psychiatric Long-acting Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 24. Global Psychiatric Long-acting Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Psychiatric Long-acting Injection Sales Market Share by Country (2019-2030)
Figure 26. North America Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2030)
Figure 27. United States Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Psychiatric Long-acting Injection Sales Market Share by Country (2019-2030)
Figure 30. Europe Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2030)
Figure 31. Germany Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Psychiatric Long-acting Injection Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Psychiatric Long-acting Injection Revenue Market Share by Region (2019-2030)
Figure 38. China Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. China Taiwan Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Psychiatric Long-acting Injection Sales Market Share by Country (2019-2030)
Figure 46. Mexico Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Colombia Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East and Africa Psychiatric Long-acting Injection Sales Market Share by Country (2019-2030)
Figure 51. Middle East and Africa Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Psychiatric Long-acting Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Psychiatric Long-acting Injection by Type (2019-2030)
Figure 56. Global Revenue Market Share of Psychiatric Long-acting Injection by Type (2019-2030)
Figure 57. Global Psychiatric Long-acting Injection Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Psychiatric Long-acting Injection by Application (2019-2030)
Figure 59. Global Revenue Market Share of Psychiatric Long-acting Injection by Application (2019-2030)
Figure 60. Global Psychiatric Long-acting Injection Price (US$/Unit) by Application (2019-2030)
Figure 61. Psychiatric Long-acting Injection Value Chain
Figure 62. Psychiatric Long-acting Injection Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Support Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Hospital OT and X-Ray, Cathode Room Doors (Hermetically Sealed Door) Market Research Report 2025

Global Children\'s DHA Market Research Report 2025

Global Marine Derived Drugs Market Research Report 2025

Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}